STERIS (STE)
(Delayed Data from NYSE)
$225.18 USD
+3.33 (1.50%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $225.18 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$225.18 USD
+3.33 (1.50%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $225.18 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
Zacks News
4 Top Growth Picks as MedTech Battle Rages On
by Zacks Equity Research
Trump's Obamacare replacement saga has made growth picks great opportunities for investors in MedTech sector.
Civitas Solutions (CIVI) Q3 Earnings Beat, Revenues Miss
by Zacks Equity Research
Civitas Solutions (CIVI) gains on strength in Post-Acute Specialty Rehabilitation Services and Adult Day Health services in Q3. However, tweaked full-year 2017 guidance signals dull prospects.
BioScrip (BIOS) Gains on CORE Initiatives, Competition Rife
by Zacks Equity Research
The company achieved annualized supply chain improvement since the acquisition of Home Solutions.
Why Is STERIS (STE) Up 3.5% Since the Last Earnings Report?
by Zacks Equity Research
STERIS (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
STERIS Continues to Trade Below Industry on Dull Outlook
by Zacks Equity Research
On Mar 16, we issued an updated research report on Ohio-based STERIS plc (STE).
STERIS (STE) Up 3.1% Since Earnings Report: Can It Continue?
by Zacks Equity Research
STERIS (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
STERIS (STE) Cuts 2017 View: Will it See Gloomy Days Ahead?
by Zacks Equity Research
On Feb 09, we issued an updated research report on Ohio-based STERIS plc (STE).
Steris (STE) Q3 Dismal: Earnings Miss Estimates, View Cut
by Zacks Equity Research
Steris Plc (STE) reported third-quarter fiscal 2017 adjusted earnings per share (EPS) of 98 cents, in line with the year-ago quarter.
Top Research Reports for December 29, 2016
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo (WFC), Danaher (DHR) and Colgate-Palmolive (CL).
Steris Poor Q2 Disappoints, Synergy Health Raises Hope
by Zacks Equity Research
On Dec 7, we issued an updated research report on OH-based STERIS plc (STE).
MedTech Tailwinds at a Glance: Which Stocks to Buy?
by Zacks Equity Research
Positive demographic trends and new product innovation have been the vital force behind the continued uptrend of the sector???s performance.
Rush in Medical Device Investments: Should You Buy These Stocks?
by Zacks Equity Research
Coming to the weakest links in the MedTech sector, we advise investors against names that offer little growth/opportunity in the near term.
Should You Buy Evolving Trends in Medical Devices?
by Zacks Equity Research
Given the U.S. government's pushback on tax-dodging, we expected some sloth to creep into the medical device space as far as M&As are concerned. But to our surprise, M&A activity worldwide has remained fairly stable.
3 Stocks For Buckeye Fans
by Brian Bolan
Ohio State takes on Oregon for the college football national championship, but investors should take a look at Ohio based stocks